Stay updated with breaking news from Myra Vision. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Myra Vision, a Shifamed portfolio company, announced today its Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System, a next-generation...
Glaucoma Research Foundation, the nation’s most experienced foundation dedicated solely to glaucoma research and education, has elected Tracy M. Valorie, BS,
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
SAN DIEGO — It may be time for a new approach to initial and stepwise interventional therapy in glaucoma, according to a speaker here.
Myra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings Company to accelerate development of the first-of-its-kind treatment for patients with moderate to severe glaucoma News provided by Share this article Share this article CAMPBELL, Calif., June 1, 2021 /PRNewswire/ -- Myra Vision, a Shifamed portfolio company, announced today the closing of its $17M Series A financings, which will be used to advance product development, scale infrastructure, and expand their team in order to support the development of the first of its kind glaucoma treatment device. The financings ...